Additional Information
Product Name: | Ixazomib (MLN-2238) |
---|---|
Also Known As: | [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid |
Catalog No.: | F1110 |
Size: | 5 mg |
CAS: | 1072833-77-2 |
Formula: | C14H19BCl2N2O4 |
Molecular Weight: | 361.03 g/mol |
Form: | Lyophilized powder |
Quality Assurance: | >98% by HPLC and NMR |
Source: | Synthetic |
Storage: | Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and ligh |
PDF Data Sheet: | Download PDF datasheet, MSDS |
Image(s): | N/A |
Shipping Method: | Room temperature shipping |
References: | N/A |
Details
Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.
Solubility:
> 10 mg/ml in DMSO, < 1mg/mL in water, For in vivo use, >30 mg/mL in 0.5% hydroxyethyl cellulose
Solubility:
> 10 mg/ml in DMSO, < 1mg/mL in water, For in vivo use, >30 mg/mL in 0.5% hydroxyethyl cellulose